Now that Amylin (AMLN) is being sold, Rodman & Renshaw's Michael King says fellow diabetes...
Now that Amylin (AMLN) is being sold, Rodman & Renshaw's Michael King says fellow diabetes firms MannKind (MNKD +6.55%) and Vivus (VVUS +0.4%) could be acquisition targets as well. It's worth noting, though, that King's speculation accompanies a mea culpa for being wrong about Amylin, whose assets he described as "mediocre."
From other sites
Bristol Myers Squibb : OPINION: From the Editor: Fill Your Bucket List Foundation grants wishes to adult cancer patientsat 4-traders.com (Mar 24, 2015)
at Benzinga.com (Feb 26, 2015)
at Benzinga.com (Feb 25, 2015)
at CNBC.com (Feb 17, 2015)
at Investor's Business Daily (Jan 27, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs